Table 3

Simple and multivariable linear regression with DAS28-AUC at 24 months as dependent variable and ACPA reactivities and treatment as covariates presented with significant results

ACPA reactivities and treatmentSimpleMultivariable
β valueP value95% CIβ valueP value95% CI
Fil307-3243.570.0110.80 to 6.34−1.440.502−5.63 to 2.76
Vim60-752.740.055−0.06 to 5.530.090.965−3.75 to 3.92
Vim2-174.910.004*1.60 to 8.233.570.0470.05 to 7.08
Pept-52.840.0430.09 to 5.59−0.320.875−4.34 to 3.70
F4-R-CIT2.880.0410.12 to 5.64−0.370.852−4.28 to 3.53
cDMARDs†, months−0.210.810−0.25 to 0.20
bDMARDs‡, months0.720.0000.44 to 1.000.660.0000.38 to 0.95
Corticosteroids§, months0.420.0000.29 to 0.560.390.0000.25 to 0.53
  • Filaggrin (Fil307-324), vimentin (Vim) 2-17, Vim60-75, mutated proteins (Pept-5) and collagen type II (F4-R-CIT). Adjusted for sex and age.

  • *Indicates p value remaining significant after correction for number of tests performed.

  • † Conventional DMARDs: methotrexate, sulfasalazine, chloroquine, myocrisine, azathioprine, ciclosporin and leflunomide.

  • ‡Biologal DMARDs: adalimumab, etanercept and infliximab.

  • §Corticosteroids ≤7.5 mg daily of prednisolone.

  • ACPA, anticitrullinated peptide antibody; bDMARDs, biologicals disease-modifying antirheumatic drugs; cDMARDs, conventional disease-modifying antirheumatic drugs.